Immunotherapy Using CAR T-cells to Target CD19 for Relapsed/Refractory CD19+ Primary CNS Lymphoma

NCT04443829 · clinicaltrials.gov ↗
PHASE1
Phase
ACTIVE_NOT_RECRUITING
Status
12
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

University College, London